DGX
Quest Diagnostics Inc
$210.17
0.29 (0.14%) Today
— up— down
Market Cap
$23.23B+18.2%
Revenue (TTM)
$11.15B+11.0%
Net Income (TTM)
$1.01B+14.9%
EPS (TTM)
9.08+14.9%
Shares Out
110.70M
110.70MP/E Ratio
22.69
22.69Forward P/E
17.64
17.64Dividend
$3.19 (1.64%)
$3.19 (1.64%)Ex-Dividend Date
Apr 6, 2026
Apr 6, 2026Open
$207.97
$207.97Previous Close
$209.88
$209.88Day Range
$206.98 – $211.29
$206.98 – $211.2952-Week Range
$164.65 – $213.50
$164.65 – $213.50Beta
0.55
0.55Volume
364.24K
364.24KAvg Volume
888.38K
888.38KAnalyst Rating
Buy
BuyExchange
NEW YORK STOCK EXCHANGE, INC.
NEW YORK STOCK EXCHANGE, INC.About DGX
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Related
News
N/AN/AN/AN/AN/A
Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry
Yahoo · 3d ago
Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs
Yahoo · 4d ago
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH
Yahoo · 4d ago
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Yahoo · 5d ago
Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients
Benzinga · 5d ago